Financial Results

Key highlights

Filter

Period

Filter by

recent search

Showing: 105 of 24 Financial Results

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.


Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.


Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…




Your dedicated contacts